Abstract:Lung cancer continues to pose a significant challenge as a prominent contributor to global cancer-related mortality. Despite the considerable strides made in therapeutic interventions within the past decade, a substantial population of patients diagnosed with non-small cell lung cancer (NSCLC) still face the grim reality of an incurable condition. In the realm of optimal management strategies for individuals afflicted with locally advanced, yet amenable to surgical resection, NSCLC, a therapeutic approach encompassing chemoradiation stands as a fundamental component. Significant strides have been made in the therapeutic landscape of NSCLC during the preceding two decades, facilitating an enhanced comprehension of the underlying disease biology, and mechanisms governing tumor progression, as well as advancements in early detection modalities and multimodal therapeutic interventions. Nevertheless, the overall rates of curative interventions and survival outcomes for NSCLC continue to exhibit a discouragingly low trajectory, particularly in the context of metastatic disease. Hence, the imperative for sustained research endeavors in the realm of novel pharmaceutical agents and combinatorial therapeutic approaches remains paramount, with the overarching objective of broadening the scope of clinical advantages conferred upon a wider demographic of patients, thereby fostering tangible improvements in outcomes pertaining to NSCLC. The primary objective of this review is to provide an all-encompassing examination encompassing the clinical application and synthetic routes of specific drugs, with the explicit aim of disseminating invaluable knowledge that can inform future research and development endeavors focused on NSCLC.

Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities

A pharmacological exploration of targeted drug therapy in non-small cell lung cancer

Recent progress in targeted therapy for non-small cell lung cancer

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer.

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies

Recent advances in non-small cell lung cancer targeted therapy; an update review

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer

Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials

Emerging Targets in Non-Small Cell Lung Cancer

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer